Private Equity
With large LBO firms grabbing the limelight and most of the capital, life can be tough for mid-market GPs on the fundraising trail. Andy Thomson finds that the sophistication of the marketing pitch often holds the key to success or failure.
7 min read · 04 January 2013
LP PROFILE 2007-08-01 Staff Writer <strong>CONTACTS</strong><br> <table> <tbody> <tr> <td>Mr. Richard Laing </td> <td>Mr. Innes Meek </td> </tr> <tr> <td>Ch
2 min read · 04 January 2013
The energy-focussed buyout shop has agreed to buy a Canadian helicopter company for C$3.7bn, the largest-ever deal in the oilfield services sector, as it looks to raise $12 billion for its next fund.
2 min read · 04 January 2013
The number of companies being exited into receivership rose to it highest level in four years as the average value of buyout firm exits dropped by slightly more than 25 percent.
2 min read · 04 January 2013
A consortium led by Virgin Group and including WL Ross has tabled a preferred bid for struggling UK bank Northern Rock. The bid provides shareholders with a way to benefit from the upside of any turnaround.
3 min read · 04 January 2013
The UK's Minister for Asia, Africa and the UN called on emerging markets managers not to shirk their social and enviromental responsibilities in the countries where they invest.
1 min read · 04 January 2013
The private equity consortium that five years ago paid $1.5 billion for Burger King continues to profit from its investment in the fast food chain. A secondary offering will raise $450 million for the firms.
2 min read · 04 January 2013
Sir David Walker has spoken out against demands for separate legislation of private equity and has defended his decision to give UK industry group the BVCA the responsibility of enforcing his proposed code of conduct.
3 min read · 04 January 2013
The firm has appointed a heavyweight legal advisory board to benefit from deregulation in the sector, which it expects to trigger a “big bang” of takeover activity.
2 min read · 04 January 2013
Biotechnology and life sciences companies require significant investment capital, and multi-million dollar investment rounds have recently grabbed headlines. But depending on the technologies being developed, the underlying research can be more or less expensive, providing many types of opportunities for investors. David Rapp spoke with leading biotech investors to learn more.
6 min read · 04 January 2013
